Lexaria Bioscience Corp. (NASDAQ: LEXX) announced an extension of its Material Transfer Agreement (MTA) with an undisclosed pharmaceutical company, referred to as PharmaCO, to continue evaluating Lexaria's DehydraTECH™ technology for oral drug delivery, specifically for GLP-1 drugs. The original agreement, dated August 30, 2024, has been extended through December 31, 2026, to allow time for PharmaCO to receive and review Lexaria's 2026 research and development results related to GLP-1.
Under the extended MTA, the temporary exclusive license remains active, enabling the two parties to engage in further strategic planning discussions with PharmaCO's human clinical and business development teams. This extension underscores the potential of Lexaria's patented DehydraTECH platform, which has repeatedly demonstrated the ability to increase bio-absorption, reduce side effects, and deliver drugs more effectively across the blood-brain barrier.
Over the past 12 months, Lexaria has made significant progress in its GLP-1 development program, including recently announced advancements in three key studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are within the GLP-1 sector and are designed to provide comprehensive evidence to facilitate further collaboration and potential licensing of Lexaria's technology. These studies are fully funded with existing corporate resources, and results are expected during the third and fourth quarters of this calendar year.
The extension is important because it signals continued interest from a major pharmaceutical company in Lexaria's drug delivery technology, which could have implications for the oral delivery of GLP-1 drugs, a class of medications used for conditions like type 2 diabetes and obesity. If successful, DehydraTECH could enable more effective oral formulations, potentially improving patient compliance and outcomes. For the industry, this partnership highlights the growing focus on enhancing drug bioavailability through innovative delivery platforms.
Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. The company's DehydraTECH platform has been evaluated in multiple studies, showing promise in improving the way a wide variety of drugs enter the bloodstream through oral delivery.
The announcement also underscores the importance of continued research and development in the GLP-1 space, which has seen significant investment and innovation. With results from Lexaria's studies expected later this year, the extended MTA provides a framework for potential future collaboration, including clinical development and commercialization.
For more information about Lexaria and its technology, visit www.lexariabioscience.com.
